Physician profile
David William Dodds
NPI 1881980142
$1,250.54
in general payments reported to CMS, 2019-2025
21 companies · $313 in 2025
The $313 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $114 · 2021: $168 · 2022: $198 · 2023: $140 · 2024: $179 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $608 · Education: $24.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.28 |
| Education | $24.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $194.58 | 2020-2021 | |
| Abbvie INC. | $149.20 | 2023-2025 | Durysta |
| Genentech USA, INC. | $141.09 | 2022-2025 | Vabysmo |
| Rxsight INC | $116.73 | 2024-2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Johnson & Johnson Surgical Vision, INC. | $91.71 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $74.68 | 2022-2025 | |
| Stryker Corporation | $74.36 | 2022 | |
| Alcon Vision LLC | $57.24 | 2019-2025 | Precision 1, Hydrus Microstent |
| Novartis Pharmaceuticals Corporation | $54.96 | 2020-2023 | |
| Kala Pharmaceuticals, INC. | $46.60 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $37.52 | 2020-2025 | Eylea Hd |
| Bausch & Lomb Americas INC. | $30.43 | 2023-2024 | Vyzulta |
| Sight Sciences, INC. | $24.84 | 2022 | |
| Amgen INC. | $24.26 | 2024 | Tepezza |
| Biotissue Holdings INC. | $24.06 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.72 | 2019 | |
| Astellas Pharma US INC | $22.01 | 2025 | Izervay |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Thea Pharma INC. | $16.78 | 2025 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $15.14 | 2022 | |
| Optos, INC. | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dodds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.